Financial Information

IR Contact

M. Sc, CEO. Andreas Gerward

Andreas has during the last 10 years worked with pharmaceutical development in smaller companies. Since joining Stayble as the CEO in 2014 Andreas has developed the company from selection of the candidate drug through preclinical development and successful clinical trials. Andreas has an engineering background and a master’s in economics and Venture Creation from Chalmers University of Technology.

andreas.gerward@stayble.se +46 (0)730 808 397

Overview

Welcome to Stayble Therapeutics AB´s IR pages

Stayble Therapeutics is a clinical pharmaceutical company developing an injection-based treatment against disc herniation. Stayble currently conducts a phase 1b within disc herniation.

LATEST PRESS RELEASES

May 8, 2025 Regulatorisk

(SV) Stayble Therapeutics AB (publ) offentliggör utfall i riktad emission av units

EJ FÖR PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA,...

Read more| Download PDF
May 6, 2025 Regulatorisk

(SV) Kallelse till årsstämma i Stayble Therapeutics AB (publ)

Aktieägarna i Stayble Therapeutics AB (publ), org.nr 559024-8372, kallas till årsstämma den 5 juni 2025 kl. 13.00 på bolagets kontor på Lennart Torstenssonsgatan 8 i...

Read more| Download PDF

LATEST FINANCIAL REPORTS

(SV) Year-end report 2024Download
(SV) - Interim report Q3 2024Download
(SV) Half-year report 2024Download
(SV) Interim report Q1 2024Download

FINANCIAL CALENDAR

INTERIM REPORT Q1 2025
21May2025
Annual meeting 2025
5June2025
INTERIM REPORT Q2 2025
20August2025
INTERIM REPORT Q3 2025
19November2025
INTERIM REPORT Q4 2025
25February2026

IR Contact

M. Sc, CEO. Andreas Gerward

Andreas has during the last 10 years worked with pharmaceutical development in smaller companies. Since joining Stayble as the CEO in 2014 Andreas has developed the company from selection of the candidate drug through preclinical development and successful clinical trials. Andreas has an engineering background and a master’s in economics and Venture Creation from Chalmers University of Technology.

andreas.gerward@stayble.se +46 (0)730 808 397